Author: Damien A. Hughes, et al.
European Journal of Anaesthesiology, June 2026
Remifentanil patient-controlled analgesia is an important alternative for laboring women who cannot receive, or choose not to receive, neuraxial analgesia. However, concerns about maternal respiratory depression, sedation, staffing, and monitoring have led to inconsistent use and wide variation among maternity units.
The Obstetric Anaesthetists’ Association developed these evidence-based recommendations to standardize patient selection, administration, monitoring, staffing, complication management, and quality assurance when remifentanil PCA is used for labor analgesia.
Why the guidance was needed
Remifentanil PCA has been used for labor analgesia for more than two decades, but previous protocols have largely been institution-specific.
Practice has varied regarding:
• Patient selection
• Remifentanil dosing
• Bolus size and lockout interval
• Use of background infusions
• Maternal oxygen supplementation
• Respiratory monitoring
• Staffing requirements
• Management of respiratory depression
• Fetal and neonatal surveillance
In 2023, the United Kingdom’s National Institute for Health and Care Excellence recommended that laboring women be informed about the full range of analgesic options, including remifentanil PCA. This increased the need for a standardized and safe approach.
Methods
The Obstetric Anaesthetists’ Association assembled an expert working group that reviewed the available literature and used a modified Delphi process to develop consensus guidance.
The literature search identified 757 articles, of which 83 full-text publications were considered relevant.
The group developed:
• 19 formal recommendations
• Six consensus statements
Recommendations were graded using the United States Preventive Services Task Force methodology. Most recommendations were assigned low or moderate certainty because high-quality randomized evidence remains limited.
Patient selection
Remifentanil PCA may be appropriate when:
• Epidural or spinal analgesia is contraindicated
• Neuraxial analgesia is declined
• Neuraxial placement has failed
• The patient requires a rapidly acting, titratable systemic opioid
• Other systemic analgesic options are inadequate or unsuitable
Women should receive clear counseling that remifentanil generally provides better analgesia than conventional systemic opioids but does not provide analgesia equivalent to a functioning labor epidural.
Patients must also understand that remifentanil can cause:
• Sedation
• Hypoventilation
• Oxygen desaturation
• Apnea
• Nausea and vomiting
• Dizziness
• Reduced ability to activate the PCA button
Patient-controlled administration
Only the laboring woman should activate the PCA device.
A partner, nurse, midwife, physician, or other person must never press the button for her. Proxy activation can result in excessive dosing because the normal safety mechanism depends on the patient becoming too sedated to request another dose.
The medication should be administered through a dedicated intravenous line or a reliably controlled line that minimizes the risk of delayed drug delivery or an unintended bolus.
The pump should be clearly labeled, programmed using a standardized institutional protocol, and protected against unauthorized changes.
Dosing
The guidance recognizes that several effective dosing regimens have been reported and that no single protocol has been conclusively established as superior.
Protocols commonly use a patient-controlled intravenous bolus based on either body weight or a fixed dose, with a short lockout period reflecting remifentanil’s rapid onset and brief duration.
The dose should be individualized according to:
• Maternal response
• Sedation level
• Respiratory rate
• Oxygen saturation
• Stage and intensity of labor
• Concurrent medications
• Maternal comorbidities
Routine background infusions are generally concerning because they can increase cumulative exposure and respiratory depression without preserving the safety advantage of patient-controlled dosing.
Monitoring requirements
Continuous maternal observation is central to safe remifentanil PCA use.
Monitoring should include:
• Continuous pulse oximetry
• Regular respiratory-rate assessment
• Frequent sedation assessment
• Blood-pressure monitoring
• Heart-rate monitoring
• Appropriate fetal monitoring based on the clinical situation
Capnography may identify hypoventilation or apnea before oxygen desaturation occurs and should be considered where available, especially in higher-risk patients.
Supplemental oxygen may reduce episodes of desaturation but does not prevent hypoventilation or apnea. Oxygen saturation alone should therefore not be relied upon as the only measure of respiratory safety.
Staffing
A trained healthcare professional should remain continuously present in the room and be responsible for direct observation of the woman.
The staff member must be able to:
• Assess sedation and ventilation
• Recognize respiratory depression
• Stop the PCA immediately
• Provide supplemental oxygen
• Perform airway maneuvers
• Begin ventilation with a bag and mask
• Summon anesthesia and resuscitation assistance
The responsible staff member should not be distracted by duties that prevent continuous observation.
Immediate anesthesia support and resuscitation equipment must be available.
Safety precautions
Each labor unit using remifentanil PCA should have a written protocol addressing:
• Eligibility and contraindications
• Prescribing responsibility
• Standard dosing
• Pump programming
• Monitoring frequency
• Staffing requirements
• Escalation criteria
• Management of sedation and respiratory depression
• Transfer to the operating room
• Discontinuation after delivery
• Neonatal assessment
Naloxone, oxygen, suction, bag-mask ventilation equipment, and emergency airway equipment should be immediately available.
The PCA should be stopped if the patient develops excessive sedation, clinically significant respiratory depression, recurrent desaturation, apnea, or inability to use the device appropriately.
Higher-risk patients
Evidence remains limited for women with significant maternal or fetal risk factors.
Additional caution is needed in patients with:
• Obstructive sleep apnea
• Significant obesity
• Respiratory disease
• Neuromuscular disease
• Concurrent sedatives or opioids
• Reduced consciousness
• Significant cardiovascular disease
• Severe maternal illness
• Anticipated difficult airway
• Compromised fetal condition
The decision to use remifentanil in these groups should involve individualized assessment by an anesthesiologist and consideration of whether the maternity unit can provide enhanced monitoring and immediate airway support.
Maternal and neonatal safety
Remifentanil crosses the placenta but is rapidly metabolized by the fetus and neonate.
Most studies have not demonstrated major neonatal harm when remifentanil PCA is used according to a structured protocol. Nevertheless, neonatal respiratory depression remains possible.
Personnel skilled in neonatal assessment and resuscitation should be available at delivery.
The medication should be discontinued promptly after birth, and the mother should continue to be monitored until sedation and respiratory risk have resolved.
Quality assurance
Hospitals offering remifentanil PCA should maintain an ongoing quality-assurance program.
Important measures include:
• Number of women receiving remifentanil PCA
• Indications for its use
• Analgesic effectiveness
• Maternal satisfaction
• Episodes of oxygen desaturation
• Sedation and apnea
• Need for airway intervention
• Conversion to neuraxial or alternative analgesia
• Maternal adverse events
• Neonatal outcomes
• Protocol deviations
Regular review of these outcomes can identify training problems, unsafe variation, and opportunities to improve care.
Clinical implications
Remifentanil PCA is not a substitute for epidural analgesia when neuraxial analgesia is safe, desired, and available.
It is, however, a valuable option when neuraxial techniques are contraindicated, unsuccessful, unavailable, or declined.
Safe use depends less on the drug alone than on the complete system surrounding its administration:
• Careful patient selection
• Informed consent
• Standardized dosing
• Continuous observation
• Appropriate respiratory monitoring
• Trained staff
• Immediate access to airway support
• Regular quality review
Important limitations
Most recommendations were based on evidence of low or moderate certainty.
There remains limited information regarding the safest dose, ideal monitoring combination, and use in women with significant maternal or fetal comorbidities.
The guidance is based partly on expert consensus because large randomized trials evaluating uncommon but serious complications are lacking.
Bottom line
Remifentanil PCA can provide effective and patient-centered labor analgesia, particularly when neuraxial analgesia is contraindicated or declined.
Its use carries a genuine risk of maternal sedation, hypoventilation, oxygen desaturation, and apnea. It should therefore be offered only in units with clear protocols, continuous direct observation, appropriate respiratory monitoring, trained personnel, and immediate access to resuscitation and airway support.
When administered within these safeguards, remifentanil PCA has an established record of effectiveness and acceptable safety. Additional research is particularly needed in higher-risk maternal and fetal populations.
Thank you to the European Journal of Anaesthesiology and the Obstetric Anaesthetists’ Association for allowing us to summarize this guidance.